The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition
Authors
Keywords
-
Journal
ONCOGENE
Volume 37, Issue 22, Pages 3022-3038
Publisher
Springer Nature
Online
2018-03-12
DOI
10.1038/s41388-018-0204-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer
- (2017) Hsiang-Hsi Ling et al. EXPERIMENTAL CELL RESEARCH
- One-pot synthesis of dextran-coated iron oxide nanoclusters for real-time regional lymph node mapping
- (2017) Chaoping Fu et al. International Journal of Nanomedicine
- Association of Adjuvant Chemotherapy With Survival in Patients With Stage II or III Gastric Cancer
- (2017) Yuming Jiang et al. JAMA Surgery
- An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients
- (2016) G. Piro et al. CLINICAL CANCER RESEARCH
- The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials
- (2016) Binghong Xiong et al. GROWTH FACTORS
- Clinical impact of tumour biology in the management of gastroesophageal cancer
- (2016) Florian Lordick et al. Nature Reviews Clinical Oncology
- In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype
- (2016) D. Bossi et al. Cancer Discovery
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells
- (2015) Kaleigh Canfield et al. CELL CYCLE
- Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival
- (2015) Xiao Xiao He et al. JOURNAL OF CLINICAL PATHOLOGY
- Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
- (2015) Xiaofeng Zheng et al. NATURE
- Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling
- (2014) Lei Zheng et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- LIM and SH3 Protein 1 Induces TGF -Mediated Epithelial-Mesenchymal Transition in Human Colorectal Cancer by Regulating S100A4 Expression
- (2014) H. Wang et al. CLINICAL CANCER RESEARCH
- Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma
- (2014) Jihun Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
- (2014) Sung Hoon Noh et al. LANCET ONCOLOGY
- Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration
- (2014) J. W. Haskins et al. Science Signaling
- Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells
- (2013) Yuji Sato et al. CANCER SCIENCE
- Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis
- (2012) Y. Y. Janjigian et al. ANNALS OF ONCOLOGY
- Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin)
- (2012) Cristina Oliveras-Ferraros et al. CELL CYCLE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
- (2011) J. T. Garrett et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab for gastric cancer treatment
- (2010) Alicia FC Okines et al. LANCET
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition
- (2008) Rebecca S. Muraoka-Cook et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search